论文部分内容阅读
目的:探讨肝爽颗粒联合恩替卡韦治疗乙型肝炎肝硬化的临床疗效。方法:选择100例乙型肝炎肝硬化患者为研究对象,将其随机均分成观察组和对照组各50例。对照组患者仅用恩替卡韦治疗,观察组患者采用肝爽颗粒联合恩替卡韦治疗,两组治疗时间均为1年。治疗结束后对两组患者的肝功能、HBV、Child-Pugh评分以及DNA与纤维化指标变化等进行观察比较。结果:经过治疗,观察组总有效率为96.0%,对照组总有效率为80.0%,两组总有效率比较差异显著(P<0.05)。治疗后两组患者的Child-Pugh评分、肝功能以及纤维化指标比较差异显著,且观察组各指标改善情况优于对照组,差异均具有统计学意义(P<0.05)。结论:肝爽颗粒联合恩替卡韦治疗乙型肝炎肝硬化疗效显著,不良反应较少,有较好的耐受性,值得临床推广应用。
Objective: To investigate the clinical effect of Ganshuang granule combined with entecavir in treating hepatitis B cirrhosis. Methods: One hundred patients with hepatitis B cirrhosis were selected as the study subjects and randomly divided into observation group (50 cases) and control group (50 cases). Patients in the control group were treated with entecavir only. Patients in the observation group were treated with Ganshuang granule combined with entecavir, and the treatment time in both groups was 1 year. After treatment, the liver function, HBV, Child-Pugh scores, changes of DNA and fibrosis indexes in two groups were observed and compared. Results: After treatment, the total effective rate was 96.0% in the observation group and 80.0% in the control group. The total effective rate was significantly different between the two groups (P <0.05). After treatment, the Child-Pugh scores, liver function and fibrosis indexes of two groups were significantly different, and the improvement of each index in the observation group was better than that in the control group, the differences were statistically significant (P <0.05). Conclusion: Ganshuang granule combined with entecavir has significant curative effect on hepatitis B cirrhosis with less adverse reactions and better tolerability, which is worthy of clinical application.